In post hoc exploratory analyses, the VTE rate of patients in the LVitDSuppNegative group was noted to be significantly higher than that in all other patient groups combined (P < .001, Cramer's V = .229). A binary logistic regression model incorporating clinical covariates also showed this grouping to be significant. Conclusion: A significant association appears to exist between lack of vitamin D supplementation and VTE occurrence in persons with acute SCI and LVitD levels. Level of Evidence: III
Introduction
Venous thromboembolism (VTE) is a continuum of pathology, of which deep vein thrombosis (DVT) and pulmonary embolism (PE) are subgroups. Unfortunately, VTE is relatively frequent and a major cause of mortality and morbidity following acute spinal cord injury (SCI). In the acute setting, persons with SCI have several risk factors that predispose them to VTE, including loss or reduction of venous blood flow secondary to paresis, 1 endothelial injury, and transient hypercoagulable state 2 due to reduced fibrinolytic activity 3 and increased blood factor VIII activity. 4 The incidence of VTE in acute SCI without thromboprophylaxis has been shown to be 47% to 100%. [5] [6] [7] [8] [9] [10] [11] The period of greatest risk for developing VTE is between 72 hours and 2 weeks postinjury, although the risk remains significantly elevated for at least 8 weeks after motor complete SCI. 2, 7, 12, 13 Pulmonary embolism is the third leading cause of death for all SCI patients in the first year postinjury, accounting for 14.9% of deaths in this group. 7, 14 It has been demonstrated that for patients with acute SCI, the risk of death due to PE is 210 times greater when compared to a similar healthy population. 7, 14 Moreover, the economic impact of VTE is significant. Tator et al found that thromboembolic disease can increase length of hospital stay for persons with acute SCI by 46% and increase costs by 35%. 15 Given the proven safety and efficacy, the use of either unfractionated or low-molecular-weight (LMW) heparin subcutaneously has become standard clinical management for prophylaxis against VTE in persons with acute SCI. 16, 17 LMW heparin has been shown to be more effective than unfractionated heparin in preventing DVT but not PE. 18 Although much less common than without chemoprophylaxis, there is still a 4% to 18% rate of VTE with use of LMW heparin prophylaxis in patients with SCI. 19, 20 In addition to chemoprophylaxis strategies utilizing LMW heparin, there may be benefits of vitamin D supplementation in patients with acute SCI, as there is literature supporting an association between vitamin D and VTE. [21] [22] [23] [24] [25] [26] [27] [28] Vitamin D is biosynthesized in the skin from 7-dehydrocholesterol and obtained through nutrition. It is modified in the liver and kidneys to form the active metabolite 1,25-dihydroxyvitamin D3 (calcitriol). Calcitriol binds to a nuclear vitamin D receptor (VDR) and may exert anticoagulant effects by upregulating the expression of the anticoagulant glycoprotein, thrombomodulin (TM), and downregulating the expression of a critical coagulation tissue factor (TF) in monocytic cells. The nuclear VDR has been found to be ubiquitous, with expression having been established in many organs of the body. 15 There is a growing body of research supporting an association between serum vitamin D and chronic metabolic, cardiovascular, and neoplastic diseases. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Evidence has shown that VDR ligands alter the expression and activity of a number of proteins that are important for coagulation. 27, [31] [32] [33] Koyama et al first proposed that calcitriol or its analogues may serve as adjunctive antithrombotic agents when they demonstrated the interaction with calcitriol and intracellular VDR upregulated TM and downregulated TF in human monocytic cells and in some acute myelogenous leukemia cells. 27 This is significant with regard to thrombogenesis because TF, a protein present in subendothelial tissue, leukocytes, and monocytes, is necessary for the initiation of thrombin formation and blood clotting. TF binds with factor VII and initiates the coagulation cascade. 27 TM, on the other hand, reduces blood coagulation by converting thrombin into an anticoagulant enzyme from a procoagulant enzyme. 27 Ohsawa et al found that calcitriol downregulated TF and upregulated TM expression in monocytic cells, and was able to counteract the procoagulant effects of tumor necrosis factor (TNF) and oxidized LDL, two known TF inducers implicated in pathologic coagulation. 31 A study by Chung et al demonstrated that the mechanism by which calcitriol acts to block TNF-induced TF expression is by inhibition of the transcription factors, nuclear factor kappaB (NF-kappaB) and activator protein 1 (AP-1) 32 In addition, there is evidence from animal models for the direct role of vitamin D in coagulation. in vivo studies of VDR knockout mice (VDRKO) by Aihara et al examined whether activation of VDR leads to antithrombotic actions. 33 Their study revealed that platelet aggregation was increased in VDRKO mice. Gene expression of antithrombin in the liver as well as of TM in the aorta, liver, and kidney was downregulated, whereas TF expression in the liver and kidney was upregulated. 33 Furthermore, VDRKO mice manifested an exacerbated multiorgan thrombus formation after exogenous lipopolysaccharide injection. 33 These results demonstrate that activation of nuclear VDR elicits antithrombotic effects in vivo, and suggest that the VDR system may play a physiologic role in the maintenance of antithrombotic homeostasis. 33 Cross et al studied genetic factors associated with DVT in the posthospitalization period in medical and surgical patients by genotyping these patients for certain diseaseassociated polymorphisms. They found two VDR haplotypes significantly associated with individuals who were experiencing both postmedical and postsurgical DVTs, suggesting that VDRs are significant in the development of DVTs. 34 In humans, an association between low levels of vitamin D and VTE in non-SCI populations has been observed. Szodoray et al studied 177 persons with systemic lupus erythematosus (SLE) from a single center data registry in Hungary and found that vitamin D levels were significantly reduced in persons with DVT compared to those without DVT. 35 Several studies have shown that venous and arterial thrombotic complications exhibit seasonal variation, with risk peaking in winter and decreasing in summer. [36] [37] [38] Lindqvist et al designed a prospective cohort study of 40 000 Swedish women and looked for an association between sun exposure and VTE. They found that Swedish women who sunbathed during the summer, on winter vacations, or when abroad, or used a tanning bed, were at 30% lower risk of VTE than those who did not. 22 Risk estimates did not change substantially after adjustment for demographic and lifestyle variables. They also found that the risk of VTE increased by 50% in the winter as compared to the other seasons, with the lowest risk found in the summer. 22 They speculated that greater ultraviolet B exposure improves a person's vitamin D status, which in turn enhances anticoagulant properties. Further evidence of seasonal variation in VTE incidence includes work by Gallerani et al, who found that Italians were admitted to the hospital with a significantly higher rate of VTE in winter months. 37, 38 In addition, there are data to suggest vitamin D may actually be of clinical value in reducing VTE incidence in persons who are at high risk. In a placebo-controlled randomized trial, Beer et al looked at the incidence of thrombotic events in persons with metastatic androgen-independent prostate cancer being treated with highdose calcitriol with docetaxel versus docetaxel and placebo. They found the calcitriol arm showed a significant reduction in thrombotic adverse events when compared with the placebo. 39 These studies support the hypothesis that low levels of serum vitamin D are independently associated with increased risk of VTE and suggest that vitamin D supplementation may have an effect on VTE development. Given the body of evidence for the role of vitamin D in the pathogenesis of VTE and the prevalence of low vitamin D in patients with SCI, a retrospective cohort study was conducted to test the hypothesis that a lack of vitamin D supplementation in persons with acute SCI who have low vitamin D levels is associated with a higher VTE risk. We investigated the prevalence of low vitamin D in the acute SCI rehabilitation patient population, the effect of vitamin D supplementation, and the effect of clinically significant variables on VTE status. Specific to our hypothesis, our analysis determined if the status of vitamin D supplementation in those with low vitamin D levels correlated with VTE incidence.
Methods

Study Population
This is an institutional review board-approved, retrospective cohort study of individuals admitted to inpatient acute rehabilitation at a level I trauma center with a diagnosis of SCI from December 2009 to January 2013. A total of 282 consecutive patients with SCI who were admitted to inpatient acute rehabilitation were entered into the study database. Patients with a diagnosis of SCI were included, and patients with an admitting diagnosis other than spinal cord injury were excluded (eg, Guillain-Barre syndrome, multiple sclerosis, and stroke). Demographic data, general characteristics, established common risk factors for VTE in the SCI population, medication use, serum vitamin D level, and VTE status were extracted from the medical record. The data were validated by four physicians involved in the study (R.E., M.T., S.M., and J.C.).
Demographics and General Characteristics
Demographic data were collected from patient admission registration information. Additional information was obtained from the rehabilitation admission notes as well as discharge summaries including the following: level of injury (paraplegia vs. tetraplegia); completeness of injury based on American Spinal Injury Association Impairment Scale (AIS); and mechanism of injury, identified as traumatic (result of accident, fall, and so on) or nontraumatic (eg, degeneration of the spinal column, tumor, and so on). Patient and injury characteristics that are known risk factors for VTE were also abstracted from the medical record.
Data from the National Spinal Cord Injury Statistical Center (NSCISC) was compared to data for the patient population in the study to ensure that the study population is an appropriate representative sample of the national SCI population. NSCISC's database is a prospective longitudinal multicenter database that currently captures data from an estimated 6% of new SCI cases in the United States.
Medications and Vitamin D Supplementation
Medical records for all patients were reviewed to identify vitamin D supplementation and the use of heparin, LMW heparin, warfarin (Coumadin), or fondaparinux. Vitamin D supplementation consisted of cholecalciferol and ergocalciferol, ranging from 800 to 7000 IU/d.
Vitamin D Levels
Serum 25-hydroxyvitamin D (VitD-25OH) levels were obtained at admission for all persons admitted to the SCI service. Until spring of 2012, VitD-25OH levels were obtained as a send-out test performed by Quest Diagnostics Laboratory by liquid chromatography-tandem mass spectrometry. Since spring of 2012, this test has been performed in-house using the same method. The 30 ng/mL VitD-25OH cutoff in the categorization of low vitamin D was based on standards set by the Endocrine Society, the National Osteoporosis Foundation, the International Osteoporosis Foundation, and the American Geriatric Society. 29, 30, 40, 41 This threshold is based on the minimum level necessary to minimize the risk of falls and fractures in older adults [42] [43] [44] and is the standard used by our hospital to define low vitamin D level.
VTE Status
Presence of VTE (DVT or PE) during acute hospital or rehabilitation stay from December 2009 to January 2013, was also abstracted from the medical record. The presence of VTE was established by looking for documentation of DVT and/or PE in the patient's rehabilitation admission note, their imaging results while in rehabilitation, as well as their acute rehabilitation discharge summary. Of note, it is standard policy for patients with SCI to undergo Doppler ultrasound of the lower extremities at their acute facility before transfer or upon admission to acute rehabilitation in order to screen for DVT. When appropriate, the presence of VTE was confirmed by clinical exam and imaging.
Statistical Analysis
Statistical analyses were performed using SPSS, version 24. Fisher's exact test, (two-tailed) was used to determine the association of vitamin D level with VTE as well as vitamin D supplementation and VTE; Cramer's V was calculated to estimate effect size/strength of association. Binary logistic regressions were performed to account for potential confounders of the association among vitamin D status, supplementation, and VTE status. These confounders included age, gender, race, etiology of injury, neurologic impairment, presence of lower extremity fractures, history of cancer, history of previous VTE, presence of heterotopic ossification, and presence of decubitus ulcer, sepsis, and depression. P-values < .05 were considered statistically significant. Table 1 ). The demographics of the individuals in this study are presented alongside data from the National Spinal Cord Injury Statistical Center (NSCISC) for comparison ( Table 1) .
Results
Data
We also recorded patient and injury characteristics that are known risk factors for VTE. This included history of decubitus ulcer, depression, sepsis, lower limb fractures, cancer, and prior VTE. The breakdown is as follows: N = 19 (6.7%), VTE with decubitus ulcer; N = 12 (4.3%), VTE with depression; N = 5 (1.8%), VTE with sepsis; N = 2 (0.7%), VTE with LE fractures; N = 5 (1.8%), VTE with cancer; and N = 1 (0.4%), VTE with history of prior VTE.
Levels of VitD-25OH in patients ranged from 4 ng/mL to 63 ng/mL, with a mean of 22 ng/mL (SD AE 10 ng/mL). The total prevalence of VTE in the population was 17% (N = 48) ( (Figure 1, A2) . The probability of developing a VTE among individuals in the NVitD group was compared to individuals within the LVitD group using the Fisher's exact test, and there was no statistically significant difference (P = .108, V = .104) (Figure 2A) .
Next we conducted an analysis incorporating the effect of vitamin D supplementation. Of the 227 individuals in the LVitD group, 78% (178/227) did not receive vitamin D supplementation, and 24% (42/178) of those individuals developed a VTE (Figure 1, B4) . In contrast, only 2% (1/49) of the individuals in the LVitD group who received supplementation developed VTE (Figure 1, B3) . In comparing individuals in the LVitD group who received vitamin D supplementation (LVitDSuppPositive) to those who did not (LVitDSuppNegative) (Figure 1, B3-B4 ), there was a significant difference in the probability of developing VTE (Fisher's exact test, P < .001, V = .226) ( Figure 2B ). However, this was not the case for individuals in the NVitD group with supplementation (NVitDSuppPositive) versus no supplementation (Fisher's exact test, P = .578, V = .140) (NVitDSuppNegative) (Figure 1 , B1-B2) ( Figure 2C ).
To test for differences in VTE rates in patients with SCI and low vitamin D without vitamin D supplementation versus normal or supplemented vitamin D patients, individuals were grouped as LVitDSuppNegative (Figure 1 (Figure 1 , B1-B3, Green Highlight). VTE rates in the LVitDSuppNegative group were significantly higher compared to the Not LVitDSuppNegative group (P < .001, V = .229) ( Figure 2D ). The decision to subdivide the data to compare LVitDSuppNegative versus all others combined was done after observing the results of the previous analysis, and therefore these results should be considered exploratory.
To account for the potential impact of confounders, the post hoc exploratory analyses also included a binary logistic regression, which demonstrated a statistically significant higher odds of presenting with VTEs in the LVitDSuppNegative group, with Exp (B) = 6.128, confidence interval [CI] = 2.373-15.825, P < .001 (Table 2) ; demographic and injury characteristics were not significant in this model. We also ran a binary logistic regression that included two predictors and an interaction effect: normal vitamin D versus low vitamin D; supplementation versus no supplementation; the interaction of vitamin D levels with supplementation. This model showed a significant effect of vitamin D supplementation: Exp (B) = .053, CI = .007-.408), P = .005, while normal versus low vitamin D Exp (B) = .432, CI = .147-1.267, P = .126 and the interaction of vitamin D levels with supplementation Exp (B) < .001, P = .999 were not significant; demographic and injury characteristics were also not significant predictors in this model.
Discussion
Our study explores the association between vitamin D and VTE in patients with SCI in the acute rehabilitation setting. Although this study cannot establish causation, the results support the hypothesis that without vitamin D supplementation, individuals with SCI and low vitamin D levels are at an increased risk for VTE. There appears to be an association between vitamin D and thrombogenicity in basic science research and human studies in non-SCI populations. [33] [34] [35] [36] [37] [38] Both in vitro and in vivo studies have demonstrated an association between vitamin D and VTE. This is a particularly relevant association to research in SCI, as individuals with SCI are known to have low levels of vitamin D and high rates of VTE. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] There may be multiple factors that predispose individuals with SCI to having low vitamin D levels, such as poor nutrition, limited exposure to sunlight, 45 nonwhite ethnicity, 45, 46 and low level of functionality. 47, 48 Bone remodeling and calcium homeostasis also contribute to the dysregulation of vitamin D levels in acute SCI, as increased bone resorption and subsequent hypercalcemia result in suppression of parathyroid hormone and vitamin D levels. 49 In this study, the majority of individuals with acute SCI admitted to inpatient rehabilitation had levels of VitD-25OH < 30, consistent with previous evidence indicating the prevalence of vitamin D deficiency to be higher in individuals with SCI. 45, 50 A unique feature and strength of this study is that the data were collected at a time before the routine clinical practice of vitamin D supplementation, allowing for evaluation of the natural history of low vitamin D levels in our patient population.
When comparing individuals with VitD-25OH ≥30 to those with levels <30 in our cohort, there was no statistically significant difference in VTE rates. However, this comparison included those with low levels who received supplementation (LVitDSuppPositive). Vitamin D supplementation in those with low vitamin D may be paramount, as supplementation with vitamin D rapidly changes 25-hydroxyvitamin D levels, 51 subsequently lowering inflammatory cytokines [52] [53] [54] and ultimately reducing the risk of thromboembolism from low levels of 25-hydroxyvitamin D. 55, 56 Moreover, the importance of accounting for supplementation was clearly demonstrated in the subgroup analysis of acute SCI patients with low vitamin D, where our results demonstrated a significantly increased probability of developing VTE if low vitamin D levels are left untreated. In further support Results from the binary logistic regression showed a significant main effect of vitamin D replacement while accounting for covariates, which may be driven by the differences in VTE occurrence in patients with low vitamin D levels ( Figure 2B ). This model did not show a significant main effect of vitamin D level (normal vs. low vitamin D) also supporting the Fisher's exact test (Figure 2A) . Although the interaction of vitamin D replacement and vitamin D levels was not significant in this model, a separate regression investigating the final grouping in the Fisher's exact test ( Figure 2D and Table 2 ) was significant after accounting for covariates. These results support vitamin D supplementation in those with low vitamin D levels as well as the need for further prospective studies.
Although this is a retrospective analysis, it seems relevant that there was only one patient receiving vitamin D supplementation who had VTE. In this case, it is important to note that vitamin D supplementation was started after the diagnosis of VTE. It should also be noted that supplementation in patients with normal vitamin D levels was not associated with improved rates of VTE, as our results for individuals in the NVitD group with supplementation (NVitDSuppPositive) versus no supplementation (NVitDSuppNegative) group, are consistent with studies that have demonstrated that increasing vitamin D levels from normal does not lower the risk of VTE. 58, 59 Although the results of our study provide support for supplementation of vitamin D in patients with SCI, there are potential limitations, as the study is retrospective and observational in design. The dose and form of vitamin D supplementation varied in the study population because there was no agreed-upon standard of care followed by the clinicians in our rehabilitation department at the time of this study. In addition, the form of vitamin D used, cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2), was not clearly documented for all patients. However, both vitamin D3 and D2 are equal in potency with no practical or clinically relevant difference between them. [60] [61] [62] In addition, the patient population represents a single acute rehabilitation hospital and results may differ in a center with differing climate and/or patient demographics, further limiting the generalizability of our results. The lack of information on degree of mobility of the patients is another limitation of this study. Given that mobility and level of function are important considerations for VTE, it is a possibility that ambulatory status is confounding our results. Another major limitation is regarding DVT prophylaxis, discerning whether patients were receiving DVT prophylaxis before VTE was not possible or reliable for those diagnosed with VTE before admission to our acute rehabilitation unit, as we did not have full access to those acute hospital records. Moreover, reliable information regarding the type and severity of VTE events was not available for all patients. Of the 43 patients who had VTE, 13 were diagnosed upon or after admission to our facility. Eleven of these 13 were receiving DVT prophylaxis with either unfractionated or LMW heparin before the diagnosis of VTE. Of the two patients who were not receiving DVT prophylaxis, one had a recent gastrointestinal bleeding incident and the other was diagnosed with a DVT immediately upon admission. None of the 13 patients who had VTE after admission to our rehabilitation unit were receiving vitamin D supplementation.
Furthermore, we can only demonstrate associations and cannot comment on causation given the lack of a true control population and/or lack of a randomly distributed exposure, as this is a retrospective study. Although we accounted for potential covariates with a logistic regression model, there may be other yet unknown and/or noncontrollable potential confounding variables that may have contributed to the results observed. Low vitamin D levels may be an unspecific marker for another diseasemodifying condition for which we are unable to fully adjust/account for in our study. In addition, we were unable to control for potentially meaningful biomarkers, which may be potential cofounders, as these data were not available for all the individuals in this study.
Conclusion
We have provided a rationale for an association between untreated low vitamin D levels and the occurrence of VTE in people with acute SCI. Results of this study are consistent with our hypothesis that the lack of vitamin D supplementation in SCI patients with low vitamin D level is associated with an increased risk of VTE during acute inpatient rehabilitation hospitalization. Although our study is retrospective in nature and causation cannot be established, it opens the door to prospective research in this area.
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